At the same time, over 72% of these cancers contain aberrations in components of RB1 pathway, such as CDKN2A (32–81%), CDK4 (3%), CCND1 (10–15%), CCNE1 (12–14%), CDK6 14–17%), and RB1 (1–5%)8,26,27,29–31. Here, RB1 is linked to cancer.